Mitesh J Borad MD

Oncology•Scottsdale, AZ

Assistant Professor of Medicine Mayo Clinic

Join to View Full Profile

13400 E Shea BlvdScottsdale, AZ 85259
Phone+1 480-301-8000

Education & Training

Tulane UniversityFellowship, Hematology and Medical Oncology, 2003 - 2005
Cedars-Sinai Medical CenterResidency, Internal Medicine, 2000 - 2003
Rutgers New Jersey Medical SchoolClass of 2000

Certifications & Licensure

CA State Medical License 2001 - Present
AZ State Medical License 2005 - 2027
LA State Medical License 2003 - 2005
American Board of Internal Medicine Medical Oncology

Clinical Trials

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors Start of enrollment: 2008 Aug 01
Completed
Phase 1, Phase 2
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma Start of enrollment: 2010 Jun 01
Completed
Phase 2
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors Start of enrollment: 2010 Jul 01
Completed
Phase 1
Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients Start of enrollment: 2011 Nov 01
Terminated
Phase 2
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery Start of enrollment: 2012 May 01
Completed
Phase 1
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers Start of enrollment: 2012 Feb 27
Completed
Phase 1, Phase 2
Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors Start of enrollment: 2012 Aug 03
ACTIVE_NOT_RECRUITING
PHASE1
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Start of enrollment: 2013 Apr 01
Terminated
Phase 1
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma Start of enrollment: 2014 Jun 01
Completed
Phase 1, Phase 2
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma Start of enrollment: 2014 Jul 23
Terminated
Phase 2
Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors Start of enrollment: 2015 Feb 18
Terminated
Phase 1
Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions Start of enrollment: 2014 Dec 01
Completed
Phase 2
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Start of enrollment: 2016 Jan 01
Completed
Early Phase 1
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Start of enrollment: 2017 May 25
Terminated
Phase 1
A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma Start of enrollment: 2018 Mar 07
Completed
Phase 2
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer Start of enrollment: 2018 Sep 26
Active, not recruiting
Phase 2
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC Start of enrollment: 2019 Sep 20
Terminated
Phase 2, Phase 3
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer Start of enrollment: 2019 Oct 18
Completed
Phase 2
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors Start of enrollment: 2021 Apr 11
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma Start of enrollment: 2021 Oct 20
Active, not recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Systemic therapy for pretreated advanced biliary tract cancer: past developments and recent advances.
Naohiro Okano, Angelo Pirozzi, Oluseyi Abidoye, Celine Hoyek, Cody Eslinger
Japanese Journal of Clinical Oncology. 2025-04-02
Transforming Hepatocellular Carcinoma Treatment in Lower Income Countries.
Channa R Jayasekera, Chrishanthi Rajasooriyar, Clayton Richards, Sanjeev Arora, Mitesh J Borad
Mayo Clinic Proceedings. 2025-04-01
CLO25-095: Baseline Genomic Alterations as Predictors of Response to Anti-HER2 Therapy in HER2-Amplified Advanced Colorectal Cancer (aCRC).
Celine Hoyek, Angelo Pirozzi, Binbin Zheng, Naoko Lida, Ryne Ramaker
Journal of the National Comprehensive Cancer Network. 2025-03-28

Journal Articles

Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma
Mohamad Bassam Sonbol, Amit Mahipal, Zhaohui Jin, Kabir Mody, Mitesh J Borad, Daniel H Ahn, Tanios Bekaii-Saab, JAMA Oncology
E6201, an Intravenous MEK1 Inhibitor, Achieves an Exceptional Response in BRAF V600E-Mutated Metastatic Malignant Melanoma with Brain Metastases
Mitesh J Borad, Raoul Tibes, Michael S Gordon, Ronald L Korn, Investigational New Drugs
Chromoanasynthesis Is a Common Mechanism That Leads to ERBB2 Amplifications in a Cohort of Early Stage HER2+ Breast Cancer Samples
Katherine B Geiersbach, Mitesh J Borad, Sarah A McLaughlin, BioMed Central

Lectures

A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) chol...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Clinical Hematology and Oncology 2013: The 10th Annual Mayo Board Review
Mayo School of Continuous Professional Development, Scottsdale, Arizona - 1/18/2013